TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06524076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: After removing caries high-speed handpiece with water coolant using a round diamond bur. Once there is an exposure, the bur is changed with another sterile one with which the superficially inflamed pulp tissue will be gently removed to a depth of 1-3 mm beneath the pinpoint pulp exposure that occurred at the end of caries removal. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete pulpotomy
Description: After removing caries with a large round bur, the access cavity will be opened. Excavation of inflamed coronal pulp tissues will be done using a sharp excavator. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
Study: NCT06433310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Phenylalanine 500 mg Veg Capsule product
Description: 500 mg Veg Capsule product
Study: NCT04163887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepatectomy
Description: Resection colorectal liver metastases using a laparoscopic approach or an open approach.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepatectomy
Description: Resection colorectal liver metastases using a laparoscopic approach or an open approach.
Study: NCT06279637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Home-DM-BAT Intervention
Description: 8 weekly sessions of telephone-delivered, manualized education on diabetes management, problem solving of social needs, and behavioral activation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Diabetes education materials will be mailed weekly and monthly according to the booster schedule
Study: NCT05607732

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MyCog
Description: MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
Study: NCT05453877

Intervention type: OTHER
Intervention: No intervention will be applied.
Description: This is an observational study.
Study: NCT06063122

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: smallTalk NICU Active
Description: The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smallTalk NICU Active
Description: The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
Study: NCT05677932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Exposure to bright light therapy for 30mins a day for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dim red light therapy
Description: Exposure to 50lux dim red light therapy for 30mins a day for two weeks
Study: NCT05235620

Intervention type: OTHER
Intervention: PatientToc use in pharmacies
Description: PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.

Intervention type: OTHER
Intervention: PatientToc use in pharmacies
Description: PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
Study: NCT05153460

Intervention type: DEVICE
Intervention: Telemetry and manual monitoring vs Contactless monitoring devices
Description: All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simultaneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device).
Study: NCT05233202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
Study: NCT05963737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PS setting strategy in pressure-support ventilated patients
Description: Use PMI guide PS setting in pressure-supported ventilated patients and keep PMI within the target range (0-2cmH2O).
Study: NCT06215001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation setting (Positive end-expiratory pressure) according to Expiratory Flow Limitation
Description: Positive End expiratory pressure will be set according to the positive end-expiratory pressure able to revert the expiratory flow limitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation setting (Positive end-expiratory pressure) not according to Expiratory Flow Limitation
Description: Positive End expiratory pressure will be set not according to the positive end-expiratory pressure able to revert the expiratory flow limitation but to a standard level of 4 cmH2O.
Study: NCT06190912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin 1
Description: Eligible participants will be treated with bryostatin over a 26-week period. Doses 1, 2, 8, and 9 of the study drug will be a loading dose 20% higher (i.e., 24 µg) than the assigned fixed dose and will be administered one week apart. Otherwise, the assigned fixed dose is 20 µg. Drug is administered intravenously (IV) by continuous infusion over 45(±5) minutes. Participants are scheduled to receive 14 doses over 26 weeks.
Study: NCT05689476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA GROUP
Description: NAVA ventilation: Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
Study: NCT05807711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Methyl Folate and methylcobalamine
Description: Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
Study: NCT06621368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: the RT program will consist of eight exercises for different body segments, namely: vertical bench press, horizontal leg press, low row, leg extension, scott curl, leg curl, triceps pulley and seated calf raise. Every 12 weeks of training, the program will be restructured with changes in the order in which the exercises are performed, the number of sets, the number of repetitions or the training system in an attempt to avoid a supposed adaptive plateau. The protocols in each stage will follow the recommendations for prescribing RT for the elderly, aiming at improving strength and hypertrophy, namely: a combination of single-joint and multi-joint exercises (free weights and machines), slow or moderate execution speed (ratio 1:2 for concentric and eccentric muscle actions, respectively), one to three sets of multiple repetitions, 8-12 RM or 10-15 RM, with recovery intervals between sets of one to two minutes, and a training frequency of two to three weekly sessions, on alternate days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control-no treatment
Description: Participants will maintain their daily activities.
Study: NCT06473844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg once daily from recruitment to hospital discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single tablet once daily from recruitment to hospital discharge
Study: NCT05064878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching ZX008 Placebo
Description: Matching ZX008 placebo is supplied as an oral solution.
Study: NCT05969964

Intervention type: BEHAVIORAL
Intervention: Avoid second resection after initial complete resection
Description: Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.

Intervention type: BEHAVIORAL
Intervention: Avoid second resection after initial complete resection
Description: Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.
Study: NCT05705193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroFlex (computerized gamified tasks)
Description: The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant.
Study: NCT04131647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Maintenance + Intermittent Fasting
Description: Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
Study: NCT05280769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral nicotine pouch - 2 mg
Description: On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral nicotine pouch - 4 mg
Description: On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral nicotine pouch - 8 mg
Description: On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco
Description: Participant's typical brand of smokeless tobacco
Study: NCT06284486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given by PO
Study: NCT06532656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/LEN FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/LEN FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/LEN FDC
Description: Tablets administered orally without regard to food
Study: NCT06311084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaginator 2.0
Description: Blended psychological digital intervention, combining Functional Imagery Training, a psychological intervention based on CBT and motivational interviewing principles, and a smartphone app.
Study: NCT00460720

Intervention type: OTHER
Intervention: Observational treatment compliance survey
Description: Observational treatment compliance survey
Study: NCT05400512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computerized cognitive training targeting the underlying cerebral networks associated with depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computerized cognitive training targeting the underlying cerebral networks associated with depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (active stimulation)
Description: A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (sham stimulation)
Description: Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
Study: NCT05164133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab
Study: NCT05282225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal follow-up
Description: This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster call
Description: The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster call
Description: The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
Study: NCT06366464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant tablet
Description: Pitolisant tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Pitolisant tablet
Description: Pitolisant tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study: NCT05290246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Limiting daily eating time to an 8 hour window

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric reduction
Description: Cut caloric intake by 15%
Study: NCT05118776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 tablets
Description: ASC40 tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo administered orally once daily.
Study: NCT05970302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
Description: Use the above medications on a regular basis.
Study: NCT05252429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2; q21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg, q21
Study: NCT04667364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
Study: NCT05840250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring and Education Support
Description: Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
Study: NCT05118776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab once every 2 weeks, intravenous drip.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab once every 2 weeks, intravenous drip.
Study: NCT06159491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
Study: NCT04773210

Intervention type: DEVICE
Intervention: Mini tube system
Description: Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment

Intervention type: DEVICE
Intervention: Conventional ligating brackets
Description: Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
Study: NCT05701956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular thrombectomy
Description: The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.
Study: NCT05160532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml of normal saline (NS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5ml of normal saline (NS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5ml of normal saline (NS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (DPT)
Description: 25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (DPT)
Description: 25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
Study: NCT06192147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein restricted diet combined with vitamin D intervention
Description: On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
Study: NCT05160532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (DPT)
Description: 25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.